All In Biotech

Drug Trial Radar · NCT03244072

Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery

Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 60,000 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

60,000

Planned (sponsor's estimate)

Start

Jun 1, 2027

Primary completion

Oct 2030

Study completion Oct 2031

Sponsor

Lead sponsor
Jason Ahee, M.D.Industry
Sponsor type
Industry
First posted
Aug 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

Conditions

  • Endophthalmitis

Interventions

  • MoxifloxacinDrug

    Intracameral injection

  • PlaceboDrug

    intracameral injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Endophthalmitis after cataract surgeryTime frame: Subjects will undergo eye examinations at one day, one week, and one month post-operatively

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zion Eye Institute

    St. George, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.